CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Clinical trials for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Armored immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple drug cocktail aims to wipe out CLL in first treatment
Disease control OngoingThis phase 2 study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—as an initial treatment for chronic lymphocytic leukemia (CLL). The goal is to see if this combo can make the cancer undetectable in the bone marrow after 15 cycles of therapy. The s…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
CLL breakthrough: stopping treatment may be possible for some patients
Disease control OngoingThis study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undetectable cancer cells after venetoclax treatment can stop taking the drug and stay in remission for at least a year. Researchers will monitor 81 participant…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising combo targets CLL in untreated patients
Disease control OngoingThis study is testing a combination of two drugs, venetoclax and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) who have not yet had treatment. The goal is to see how well this therapy controls the disease and improves survival. About 100 fit adults with CLL will…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC